Pharmas next decade wont be won by who files the mostitll be won by who avoids the safe portfolio trap.
Drugmakers have spent years optimizing for predictability: fewer filings, lower upfront legal spend, narrower scope, and portfolios engineered to lo…
The Safe Patent Portfolio Trap: Why Minimal Filing Costs Pharma a Decade of Growth Read Post »
A $50 million notice letter sounds like just another regulatory formalityuntil you realize how much damage a single Paragraph IV filing can do when its written poorly, supported weakly, and prosecuted aggressively.
Thats the real lesson behind a cautio…
The At-Risk Launch: When the Math Says Go Even If the Court Says No
A case is pending. An injunction is in the docket. The legal posture looksat least on paperlike a stop sign.
And then the spreadsheets win.
In pharma, the at-risk launch is the industr…
The At-Risk Launch: When the Math Says Go, Even If the Court Says No Read Post »
Evergreening is realbut the 20-patent thicket story is often too neat.
Regulators, investors, and pharma leaders all talk about evergreening as if its a single play: patent stacking to delay competition. But the truth is less cinematicand more operat…
The Evergreening Myth: How to Spot the Cracks in a 20-Patent Thicket Read Post »
Patent litigation is often treated as a long, expensive sloguntil it isnt.
Heres the quiet reality: the early win rarely just ends a case. It can rewire an entire commercial timeline. And in pharma, where regulatory review cycles and launch sequencing …
Sue Early, Win Big: The Hidden ROI of Challenging Weak Method-of-Use Drug Patents Read Post »
The 180-Day Exclusivity Trap: Why First-to-File Winners Still Lose Money
The loudest promise in generic drug litigation is simple: be the first to file, win 180 days of market exclusivity.
Its a strategy that has made headlines, guided investment dec…
The 180-Day Exclusivity Trap: Why First-to-File Winners Still Lose Money Read Post »
Defaulting to settlement in drug patent cases can be the most expensive habit in pharma. The math behind many court strategies is increasingly unforgivingand the pricing, timing, and probability assumptions that feel reasonable in a spreadsheet can col…
Drug patents are often sold as impenetrable fortressesuntil you zoom in on the real battlefield. The most decisive cracks rarely appear at the main gate. They show up first at the weakest wall: device patents.
Thats the core argument behind this DrugPa…
Why Device Patents Crack First: The Weakest Wall in Your Drug’s Patent Fortress Read Post »
A new patent didnt solve anythingit just reset the clock.
Drugmakers call it innovation. Patients often experience it as dj vu. And payers? They see the bill come due again.
This is the salt change trap: when a company switches the salt form of an ex…
The Salt Change Trap: When a New Patent Buys You Nothing Read Post »
Six months. Thats the headline number in pediatric exclusivityan extra runway of market protection that sounds like a win for patients, innovators, and everyone who wants better medicines faster.
But the premise is more complicated than the promise.
In…
The Six-Month Fuse: Why Pediatric Exclusivity Is a Liability, Not a Shield Read Post »
Get new actionable insights and updates from BiotechBlog
